StreetInsider.com News Articles

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

Raymond James sees a 'unique buying opportunity' in this stock

Tue, 02 Jun 2026 16:00:00 -0400

Raymond James believes the recent selloff in one biopharmaceutical company’s shares has created an attractive entry point for investors, arguing that disappointment surrounding the company's vormatrigine program does not alter its core investment thesis.

In a research note, Raymond James analyst Tiago Fauth reiterated a Strong Buy rating on Praxis Precision Medicines (NASDAQ: PRAX) and maintained a Strong Buy rating despite a failed readout from the company's POWER1 study.

“Vorma’s miss, while unexpected, creates a buying opportunity without undermining Praxis’s two core value drivers (ulixa and relu),” Fauth wrote, adding that the setback is “effectively handing investors a cheaper way to underwrite

Raymond James sees a 'unique buying opportunity' in this stock

Tue, 02 Jun 2026 16:00:00 -0400

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $616 at Truist Securities

Tue, 02 Jun 2026 08:59:25 -0400

(Updated - June 2, 2026 8:59 AM EDT)

Truist Securities analyst Danielle Brill lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $616.00 (from $715.00) while maintaining a Buy rating.

The analyst commented: "Our Initial Take On What Went Wrong and Lowering PT to $616 (from $715); Praxis announced this evening that the Phase 3 POWER1 trial with vormatrigine in focal onset seizures (FOS) failed to achieve its primary endpoint. The company is also pausing enrollment in the ongoing POWER2 trial, pending further review of the data, to determine the most appropriate next steps for the asset's development. We

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $616 at Truist Securities

Tue, 02 Jun 2026 08:59:25 -0400

(Updated - June 2, 2026 8:59 AM EDT)

Truist Securities analyst Danielle Brill lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $616.00 (from $715.00) while maintaining a Buy rating.

Praxis Precision Medicines Inc. (PRAX) PT Lowered at TD Cowen Following Vormatrigine Miss

Tue, 02 Jun 2026 08:49:43 -0400

(Updated - June 2, 2026 8:49 AM EDT)

TD Cowen analyst Ritu Baral lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $550.00 (from $554.00) while maintaining a Buy rating.

The analyst commented: "Vormatrigine Misses In Ph2/3 POWER1 FOS Study; Vormatrigine missed the 1o EP in the Ph2/3 POWER1 FOS trial, although the 2o EP of ≥50% responder rate was nominally met, and dose dependent improvement was seen. Ph3 POWER2 enrollment was paused to consider potential trial modifications; updates are due summer. We see no readthrough to the Ph3 relutrigine EMERALD all DEEs trial, and still model approval in

Praxis Precision Medicines Inc. (PRAX) PT Lowered at TD Cowen Following Vormatrigine Miss

Tue, 02 Jun 2026 08:49:43 -0400

(Updated - June 2, 2026 8:49 AM EDT)

TD Cowen analyst Ritu Baral lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $550.00 (from $554.00) while maintaining a Buy rating.

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $650 at Oppenheimer

Tue, 02 Jun 2026 07:40:12 -0400

Oppenheimer analyst Jay Olson lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $650.00 (from $750.00) while maintaining a Outperform rating.

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $1,201 at H.C. Wainwright

Tue, 02 Jun 2026 06:55:37 -0400

(Updated - June 2, 2026 6:55 AM EDT)

H.C. Wainwright analyst Douglas Tsao lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $1,201.00 (from $1,245.00) while maintaining a Buy rating.

The analyst commented: "Last night, Praxis announced that POWER1 did not meet the primary endpoint in adjunctive FOS, and that the company is pausing enrollment in POWER2 while it reassesses the vormatrigine program and considers potential modifications. While we are clearly disappointed in the primary endpoint miss, vormatrigine met the 50% responder-rate secondary endpoint and showed a more pronounced reduction in seizure frequency during the 30mg portion of the

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $1,201 at H.C. Wainwright

Tue, 02 Jun 2026 06:55:37 -0400

(Updated - June 2, 2026 6:55 AM EDT)

H.C. Wainwright analyst Douglas Tsao lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $1,201.00 (from $1,245.00) while maintaining a Buy rating.

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $400 at Baird

Tue, 02 Jun 2026 06:16:36 -0400

Baird analyst Brian Skorney lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $400.00 (from $433.00) while maintaining a Outperform rating.

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $810 at BTIG

Tue, 02 Jun 2026 05:03:12 -0400

BTIG analyst Kambiz Yazdi lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $810.00 (from $843.00) while maintaining a Buy rating.

The analyst comments "We will be straightforward: we were wrong on our POWER1 call. POWER1 did not meet its primary measure of percent change in monthly seizure frequency from baseline in highly refractory FOS patients, a result we did not anticipate. We lower our price target to $810 (from $843), reflecting a reduction in our vormatrigine PoS to 50% (from 70%). While POWER1 is a setback, the vormatrigine program is not without a recoverable path. The 50%

Praxis Precision Medicines Inc. (PRAX) PT Lowered to $810 at BTIG

Tue, 02 Jun 2026 05:03:12 -0400

BTIG analyst Kambiz Yazdi lowered the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $810.00 (from $843.00) while maintaining a Buy rating.

Form 8-K Praxis Precision Medicin For: Jun 01

Mon, 01 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26584155.html

Form 8-K Praxis Precision Medicin For: Jun 01

Mon, 01 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26584155.html

Praxis pauses vormatrigine study after trial misses primary endpoint

Mon, 01 Jun 2026 16:15:42 -0400

Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures failed to meet its primary endpoint, prompting the company to pause enrollment in a second study while it reassesses the program.

The POWER1 study evaluated vormatrigine in adults with focal onset seizures who were taking one to three anti-seizure medications. Patients received either 20 mg daily for six weeks followed by 30 mg daily for six weeks, or placebo for 12 weeks. The primary endpoint measured the percent change in monthly seizure frequency from baseline.

While the study did not meet its primary

Praxis pauses vormatrigine study after trial misses primary endpoint

Mon, 01 Jun 2026 16:15:42 -0400

While the study did not meet its primary

Praxis pauses vormatrigine study after trial misses primary endpoint

Mon, 01 Jun 2026 16:15:42 -0400

While the study did not meet its primary